Pevion Biotech hires new ceo

Also secures CHF10m of financing

Pevion Biotech, a vaccine developer based in Berne, Switzerland, has appointed Evert Kueppers as chief executive, succeeding Thomas Stauffer.

Prior to joining Pevion, Kueppers was ceo of Pieris, a Munich-based biotechnology company, which he successfully restructured and refinanced, raising a total US$45m. Before joining the biotech industry, he spent several years in the International Operations of BASF Pharma (now Abbott Labs) and was a management consultant with the global healthcare team of AT Kearney in London.

The company has also secured further financing of CHF10m from its existing investors, BZ Bank, BB Biotech Ventures and Core Capital.

Pevion says it plans to raise additional financing over the next 12 months to broaden its pipeline.

‘Pevion has reached an important stage in its development as its candidate products reach for critical milestones. This financing commitment should take the company a long way towards achieving further product validation,’ said Joseph Manko of BZ Bank and member of the Board of Directors.

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Finance

Heligan Group report: UK healthcare M&A remains resilient

A new report from the investment group has highlighted the healthcare field as being a "defensive, structurally supported sector"
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Subscribe now